Prognostic Value of CD56 Expression in Multiple Myeloma

Khallaf, Salah; Yousof, Eman A.; Ahmed, Ehab A.; Mansor, Shymaa G.; Mohamed, Hanan O.; Elgammal, Sahar A.; Moeen, Sawsan M.; Sayed, Doaa M.

doi:10.21608/resoncol.2020.24758.1091

Cited by 5 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the present study, hypercalcemia (Ca > 11 mg/dL) was found in 38.3% of patients and a similar ratio was found in the study by Khallaf et al, 2020 [ 15 ]. Median Serum creatinine of 1.7 mg/dL was detected in the present study which was about the same result 1.7 ± 2.1 detected by Udupa et al, 2020 [ 2 ].…”

Section: Discussionsupporting

confidence: 91%

“…Median Serum creatinine of 1.7 mg/dL was detected in the present study which was about the same result 1.7 ± 2.1 detected by Udupa et al, 2020 [ 2 ]. Renal impairment (serum creatinine > 2 mg/dL) in our study was detected in 38.3% of patients but a lower ratio was detected in 2020 by both Khallaf et al and Warnnissorn et al [ 15 , 16 ]. The higher ratio of renal impairment in this study may be attributed to the higher ratio of renal failure among Africans as stated by an African study in 2018 by Cisse et al [ 17 ].…”

Section: Discussioncontrasting

confidence: 53%

See 1 more Smart Citation

Clonal heterogeneity by fluorescence in situ hybridization in multiple myeloma: enhanced cytogenetic risk stratification

Abdel-Qader

Fouad

Abuelela

et al. 2022

Egypt J Med Hum Genet

View full text Add to dashboard Cite

Background Multiple myeloma (MM) is a proliferation of monoclonal plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. Cytogenetic analysis is a challenge in MM because of the low mitotic activity and the rapid loss of plasma cells viability in bone marrow culture. Adding mitogens such as interleukin 6 (IL6) is known to promote the in vitro growth of myeloma cell lines and enhance the fluorescence in situ hybridization application. This study aims to evaluate the prognostic impact of cytogenetic abnormalities detected by enhanced interphase fluorescence in situ hybridization (iFISH) technique in Egyptian MM patients. Results Patients who had hyperdiploidy significantly presented with higher Hb level and lower calcium levels compared to non-hyperdiploid patients. They were staged as stage I and II by International staging system (ISS) and considered as standard risk showing better response to treatment. On the contrary, features associated with a worse outcome were patients having del 17p and those belonged to intermediate and high risk groups. Conclusion In conclusion, adding interleukin 6 to MM cell culture promotes the in vitro growth of myeloma cells and enhances the successful application of FISH technique. A comprehensive FISH probe set investigating high, intermediate and low-risk cytogenetic abnormalities is needed for accurate risk stratification. Hyperdiploid-myeloma is a favorable risk genetic subtype of MM associated with rapid response to therapy compared to patients having del 17p, t(4;14), and other 14q rearrangements rather than t(11;14) and t(6;14).

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussioncontrasting

confidence: 53%

Clonal heterogeneity by fluorescence in situ hybridization in multiple myeloma: enhanced cytogenetic risk stratification

Abdel-Qader

Fouad

Abuelela

et al. 2022

Egypt J Med Hum Genet

View full text Add to dashboard Cite

show abstract

“…This has been the explanation for the leukemic phase of MM being more frequent in patients without CD56 expression in PCs [52]. The absence of CD56 in MM plasma cells was associated with poor prognosis, more aggressive disease [37] and lower PFS [11,19,38] and OS [41,53], however this association was not consensual [9]. Our study showed that the absence of CD56 in clonal PC was associated to significantly higher probability of OS and PFS post ASCT.…”

Section: Discussionmentioning

confidence: 55%

Immunophenotypic Markers Associated with Minimal Residual Disease Status and Outcome in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

Missassi¹,

MRV²,

CM³

et al. 2021

annhematoloncol

View full text Add to dashboard Cite

Multiple Myeloma (MM) is one of the most common hematologic malignancies, with a heterogeneous prognosis. Therefore, the recognition of biomarkers can be useful to understand the differences in patient outcomes. Minimal Residual Disease (MRD) has been considered a very important prognostic factor in MM. In parallel, the prognostic value of immunophenotypic markers expressed in MM Plasma Cells (PCs) has also been described. The aim of this study was to assess the impact of CD27, CD28, CD45, CD56, CD117 and β2-microglobulin expressions on the outcome of 154 MM patients undergoing Autologous Stem Cell Transplantation (ASCT). The relation of each marker studied with the Overall Survival (OS) and Progression-Free Survival (PFS) was assessed, alone and in association with pre-ASCT MRD. Scores of good (GPM) and poor Prognostic Markers (PPM) were established, according to their respective survival curves. The expressions of CD27 and CD45 were associated to longer OS (p=0.013 and p=0.00, respectively) and PFS (p=0.00) as well as the absence of CD28 (OS p=0.026; PFS p=0.001) and CD56 (OS p=0.004; PFS p=0.009), in patients with undetectable MRD. The number of GPM showed an inverse correlation with the level of MRD (p=0.04), while a higher number of PPM was observed in patients with higher levels of MRD (p=0.04), which were also significantly associated with OS and PFS. In conclusion, although pre-ASCT MRD is a powerful prognostic factor in MM, these biomarkers can provide additional prognostic information and be used in the follow-up of MM patients.

show abstract

“…По данным некоторых источников, пациенты с ММ с CD56 + имеют более благоприятный прогноз [9], однако в исследовании S. Khallaf и соавт. присутствие данного маркера на ПК было связано с неблагоприятным прогнозом и низкой беспрогрес сивной выживаемостью [10]. При исследовании ИГХ маркеров на опухолевых ПК в нашем исследовании выявлено значимое превышение CD56 + у пациентов с МГНЗ с последующей прогрессией.…”

Section: Discussionunclassified

Significance of bone marrow immunohistochemical analysis in patients with plasma cell neoplasms

et al. 2023

View full text Add to dashboard Cite

Background. The group of plasma cell neoplasms includes benign and malignant diseases. Sometimes there are difficulties in making a diagnosis. The study of the diagnostic and prognostic significance of immunohistochemical (IHC) markers is of current interest.Aim. To study the significance of IHC markers and histological features of the bone marrow in primary diagnosis in patients with multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS).Materials and methods. The study included 287 patients with plasma cell neoplasms: MGUS (n = 148), MM (n = 139). The observation period was 50 months. All patients have performed an aspiration biopsy and histological examination of the bone marrow with IHC analysis of CD138+, CD56+, CD34+, κ- and λ-chains expression.Results. During the observation period the progression of MGUS to MM was recorded in 8.8 % (n = 13) of cases, the progression of MM was determined in 38.1 % (n = 53) of cases.In patients with MGUS and MM the determined percentage of plasma cells at aspiration biopsy was somewhat lower than at histological examination (p >0.001). Statistically significant differences were determined between the groups MGUS and MM by the type of infiltration (р <0.001). With an increase in the percentage of bone marrow lesions by IHC (<20 % vs. 20–50 % and 20–50 % vs. >50 %), in our study interstitial and diffuse type of lesion with large accumulations was more common compared to the nodular type (p = 0.001).The CD138+ expression (IHC) more than 10 % was associated with a decrease of progression-free survival in patients with MGUS.In MM patients with an interstitial type of bone marrow infiltration and CD138+ over 10 % osteodestructive syndrome was detected by X-ray methods in 82.9 % of cases.Determination of CD56+ and immunoglobulin light chains expression in patients with MM and MGUS indicated an unfavorable prognosis.Resistance to chemotherapy or disease progression in MM patients most often occurred with a combination of IgG and immunoglobulin light chains secretion, with CD138+ plasma cells more than 50 % according to IHC, with a diffuse type of bone marrow lesion with accumulations of plasma cells. MGUS patients progressed more frequently with more than 20 % CD138+ plasma cells according to IHC, interstitial type and diffuse plasma cells accumulation type of bone marrow lesion, secretion of IgG or two immunoglobulins.Conclusion. The significance of the IHC study in the diagnosis of plasma cell neoplasms was confirmed. Markers associated with the disease progression and chemotherapy resistance in patients with MGUS and MM were identified.

show abstract

Prognostic Value of CD56 Expression in Multiple Myeloma

Cited by 5 publications

References 17 publications

Clonal heterogeneity by fluorescence in situ hybridization in multiple myeloma: enhanced cytogenetic risk stratification

Clonal heterogeneity by fluorescence in situ hybridization in multiple myeloma: enhanced cytogenetic risk stratification

Immunophenotypic Markers Associated with Minimal Residual Disease Status and Outcome in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

Significance of bone marrow immunohistochemical analysis in patients with plasma cell neoplasms

Contact Info

Product

Resources

About